Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (5189)	8/19/1998 4:20:00 PM
From: Steve Fancy	of 6136

>>And the ten point drop has nothing to do with IR. Try the "Great Sustiva hype" and the emphasis on side effects of protease inhibitors. The side effects of NNRTI's have been ignored, and there are a lot more dropouts and side effects from NNRTI's than have been acknowledged.<< You hit the nail on the head Margie...a massive communication problem. Seems to me that's IR. The most recent blunder was creating uncertainty during the conference call regarding the oncology spin-off. Should have waited till they had solid details. If AGPH's problems of late are other then communication, then we're probably all in trouble. sf sf

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next